Neovacs S.A.

Neovacs obtains FDA ‘Fast Track’ designation for IFNα Kinoid in Lupus (SLE)

Neovacs signs production partnership with 3P Biopharmaceuticals, a leading GMP producer of biological drugs

NEOVACS ACQUIRES INTERFERON ALPHA MANUFACTURING TECHNOLOGY FROM AMEGABIOTECH

Neovacs enrolls the first U.S. Patient in Phase IIb study of IFNa Kinoid for treatment of Systemic Lupus Erythematosus (SLE)

Neovacs to attend Jefferies 2016 London Healthcare Conference November 16 & 17, 2016

Neovacs S.A. signs a cooperation agreement with the Department Immunology of Diabetes at the reputed Hospital Cochin in Paris

Neovacs S.A.: Half-year results 2016 and update on operational development

Neovacs to present at two major Investor Conferences

Neovacs and Stellar Biotechnologies Announce Launch of Neostell, Joint Venture to Manufacture Kinoids

Neovacs to Present at Bio International Convention 2016

Neovacs to attend ChinaBio(R) Event May 18 & 19, 2016

Neovacs and Stellar Biotechnologies sign a joint venture agreement to create Neostell SAS

Neovacs obtains FDA approval to extend its Phase IIb clinical trial in Lupus to United States

NEOVACS OBTAINS SOUTH KOREA HEALTH AUTHORITY APPROVAL FOR IND APPLICATION WITH INFα KINOID IN LUPUS

NEOVACS REPORTS FULL YEAR 2015 FINANCIAL RESULTS

Neovacs S.A.: 2016 Financial Calendar

Neovacs associates Stellar Biotechnologies in its industrial Project

Neovacs secures EUR5 million from the public funding program «Investments for the Future» to support clinical and industrial development for the therapeutic vaccine INFα Kinoïd

Neovacs signs a strategic partnering agreement with the Korean company CKD Pharmaceutical Corp.

Neovacs announces its engagement in the field of immunotherapy in cancer, following the recommendation of its Scientific Advisory Board which met in New York on the 17th of November

NEOVACS ANNOUNCES ITS PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

NEOVACS REPORTS FIRST-HALF 2015 FINANCIAL RESULTS

NEOVACS INITIATES PHASE IIb TRIAL OF IFNα-KINOID FOR THE TREATMENT OF LUPUS

NEOVACS CONFIRMS POTENT AND LONG-LASTING BIOLOGICAL ACTIVITY OF IFNα-KINOID 4 YEARS AFTER PATIENT DOSING IN PHASE I/IIa TRIAL

NEOVACS RECEIVES FIRST REGULATORY APPROVALS FOR A PHASE IIb TRIAL OF IFNα-KINOID IN LUPUS

NEOVACS ANNOUNCES CLOSING OF 7.5M EURO CAPITAL INCREASE WITH U.S. INSTITUTIONAL INVESTORS

NEOVACS RAISES 7.5 MILLION EUROS IN CAPITAL INCREASE WITH U.S. INSTITUTIONAL INVESTORS

NEOVACS INITIATES CLINICAL PROGRAM IN DERMATOMYOSITIS

NEOVACS TO PRESENT AT 2015 BIO INTERNATIONAL CONVENTION

NEOVACS TO PRESENT AT CHINA BIO PARTNERING FORUM